In today's rapidly changing and fiercely competitive business landscape, it is essential for investors and industry enthusiasts to thoroughly analyze companies. In this article, we will conduct a comprehensive industry comparison, evaluating Regeneron Pharmaceuticals (NASDAQ:REGN) against its key competitors in the Biotechnology industry. By examining key financial metrics, market position, and growth prospects, we aim to provide valuable insights for investors and shed light on company's performance within the industry.
Regeneron Pharmaceuticals Background
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
---|---|---|---|---|---|---|---|
Regeneron Pharmaceuticals Inc | 31.96 | 4.42 | 9.42 | 2.73% | $0.83 | $2.71 | -0.54% |
AbbVie Inc | 50.01 | 37.06 | 5.47 | 14.8% | $4.49 | $8.22 | 0.7% |
Amgen Inc | 47.16 | 35.27 | 6.01 | -2.01% | $2.15 | $4.25 | 21.98% |
Vertex Pharmaceuticals Inc | 31.85 | 6.83 | 12.56 | 6.09% | $1.34 | $2.35 | 13.3% |
Gilead Sciences Inc | 196.72 | 5.03 | 3.24 | -20.66% | $-3.54 | $5.13 | 5.26% |
Biogen Inc | 27.70 | 2.12 | 3.34 | 2.62% | $0.68 | $1.75 | -7.0% |
BioNTech SE | 164.21 | 0.93 | 6.83 | -1.57% | $-0.29 | $0.13 | -85.31% |
Genmab A/S | 21.94 | 3.56 | 6.75 | 4.13% | $1.72 | $3.96 | 46.19% |
Biomarin Pharmaceutical Inc | 79.80 | 3.17 | 6.60 | 1.77% | $0.14 | $0.52 | 8.79% |
Neurocrine Biosciences Inc | 40.06 | 6.22 | 7.63 | 1.88% | $0.04 | $0.51 | 22.57% |
United Therapeutics Corp | 15.50 | 2.72 | 6.52 | 5.42% | $0.43 | $0.6 | 33.7% |
Sarepta Therapeutics Inc | 355.05 | 15.01 | 10.35 | 3.97% | $0.05 | $0.36 | 63.1% |
Incyte Corp | 19.47 | 2.35 | 3.86 | 3.2% | $0.26 | $0.82 | 8.93% |
Roivant Sciences Ltd | 2.20 | 1.42 | 76.55 | -2.51% | $-0.18 | $0.02 | 5.68% |
Average | 80.9 | 9.36 | 11.98 | 1.32% | $0.56 | $2.2 | 10.61% |